Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Diorasis Therapeutics, a Boston-based biotechnology company focused on gene therapies for glaucoma and other ophthalmic diseases, has appointed Dr. Dimitri Azar to its Board of Directors12.
Dr. Azar is a Distinguished Professor of Ophthalmology at the University of Illinois College of Medicine and President & CEO of Lacristat.AI, with past board leadership at Novartis and advisory roles at Verily, Alphabet’s life sciences research arm12.
He has significant industry experience, including serving as Senior Director at Verily and as the founding CEO of Twenty Twenty Therapeutics, where he developed novel diagnostic and therapeutic technologies in glaucoma and other eye diseases12.
Diorasis Therapeutics is advancing a first-in-class gene therapy for glaucoma, with their lead program progressing to clinical development following a successful pre-IND meeting with the FDA and the commencement of GMP manufacturing12.
Dr. Azar highlighted the company's patient-focused mission to deliver durable, disease-modifying treatments for glaucoma beyond chronic, burdensome therapies12.
Diorasis’s therapeutic platform aims for long-term efficacy from a single in-office gene therapy dose, addressing underlying disease mechanisms rather than just symptoms12.
Sources:
1. https://www.biospace.com/press-releases/diorasis-therapeutics-welcomes-dr-dimitri-azar-to-its-board-of-directors
2. https://www.businesswire.com/news/home/20251017647942/en/Diorasis-Therapeutics-Welcomes-Dr.-Dimitri-Azar-to-Its-Board-of-Directors